According to the provided sources, Cosentyx (secukinumab) is a medication used to treat various conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The recommended dosage changes for Cosentyx depend on the specific condition being treated.
For plaque psoriasis, the recommended initial dose of Cosentyx is 300 mg administered as two subcutaneous injections of 150 mg each. This is followed by a maintenance dose of 300 mg every four weeks. However, some patients may benefit from a higher dose of 300 mg every two weeks. The decision to increase the dosage to 300 mg every two weeks should be based on the patient's clinical response.
For psoriatic arthritis, the recommended initial dose of Cosentyx is 150 mg administered as two subcutaneous injections of 75 mg each. This is followed by a maintenance dose of 150 mg every four weeks. However, some patients may benefit from a higher dose of 300 mg every four weeks. The decision to increase the dosage to 300 mg should be based on the patient's clinical response.
For ankylosing spondylitis, the recommended initial dose of Cosentyx is 150 mg administered as two subcutaneous injections of 75 mg each. This is followed by a maintenance dose of 150 mg every four weeks. However, some patients may benefit from a higher dose of 300 mg every four weeks. The decision to increase the dosage to 300 mg should be based on the patient's clinical response.
It is important to note that the dosage changes mentioned above are general recommendations and may vary depending on individual patient factors. It is always best to consult with a healthcare professional for personalized dosage recommendations and any necessary adjustments.
Sources:
[1] Drug Patent Watch. (n.d.). Cosentyx. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] Cosentyx. (n.d.). Treatment & Dosing. Retrieved from https://www.cosentyx.com/plaque-psoriasis/treatment-dosing
[3] Novartis Pharmaceuticals Corporation. (2019). Cosentyx (secukinumab) [Prescribing Information]. Retrieved from https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf